Amgen is getting down with Disco Pharmaceuticals, commissioning the German outfit to work on cancer therapies focused on a ...

According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...

In early January 2026, DISCO Pharmaceuticals announced it had granted Amgen exclusive global rights to develop and ...

The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...

Amgen (NASDAQ:AMGN) remains a major biotechnology name as nasdaq composite discussions highlight healthcare innovation.

A rendering of Amgen's new science and innovation center in Thousand Oaks. (courtesy photo) Thousand Oaks-based Amgen started the new year with excitement by adding to its robust oncology pipeline.

Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...

Amgen Inc. has acquired cancer drug developer Dark Blue Therapeutics Ltd. in a deal worth as much as $840 million, expanding its portfolio of oncology treatments.

Amgen has bought cancer biotech Dark Blue Therapeutics in a deal that could be worth as much as $840mn, marking the latest ...

The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...

Amgen is committed to reducing drug costs, expanding its AmgenNow program, and investing in US manufacturing to gain tariff ...

Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...